Merck’s Delstrigo and Pifeltro Receives CHMP Approval for the Treatment of HIV-1 Infection in EU

Shots:

• CHMP approval is based on two P-III trials i.e. DRIVE-AHEAD and DRIVE-FORWARD assessing (Delstrigo vs efavirenz (EFV)/emtricitabine (FTC)/TDF) and (Pifeltro vs darunavir +ritonavir +FTC/TDF/abacavir (ABC)/3TC)) for 48 wks., showing its safety and efficacy

• On 30 Aug, 2018 the US FDA approved Delstrigo and Pifeltro for the treatment of HIV-1 infection in adult with no prior antiretroviral treatment administering qd PO with or without food. Marketing authorization for Delstrigo and Pifeltro are under review in other countries, including Canada, Australia, and Switzerland

• Delstrigo (doravirine/lamivudine/tenofovir disoproxil fumarate) is a combination of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg) administered qd FD and Pifeltro (doravirine) is a 100 mg non-nucleoside reverse transcriptase inhibitor (NNRTI) administered combining antiretroviral medicines

Click here to read full press release/ article | Ref: Merck | Image:  Gamelearn